Integrated Biology Solutions Unlocking the Combined Powers of Proteomics, Genomics, Transcriptomics and Metabolomics
Increasingly, the inherent complexity of biology requires researchers to find answers by using multiple “omics” approaches. Whether studying the causes and treatments of disease, or the underlying mechanisms of compound toxicity, integrated multi-omics research can yield groundbreaking insights.
With analytical products across all four major “omics”—genomics, transcriptomics, proteomics and metabolomics—and the latest version of GeneSpring bioinformatics software for pathway-centric multi-omic data integration, Agilent is committed to helping researchers achieve new milestones in multi-omics discovery and advance the field of Integrated Biology.
Answers Emerge Through Integrated Analyses
While genomics, transcriptomics, proteomics, and metabolomics are in wide use, these experiments, performed alone, often lack the statistical power to uncover meaningful correlations amid the high levels of noise omics experiments typically generate.
Figure 1: The statistical power of omics experiments can be enhanced through bioinformatics methods that decrease noise through the use of (1) complementary datasets, and (2) incorporation of prior knowledge about the system (e.g., aggregating measurements from entities that belong to the same pathway). This results in an effective decrease in the False Discovery Rate (FDR), at a given t statistic cutoff, or in the ability to relax such cutoff while maintaining the same FDR.
Figure 2: Agilent supports and integrates single and multi-omics experiments, simplifying the researcher’s cyclical journey between hypothesis-free discovery and pathway/hypothesis-driven validation
Learn more at Pathways to Insight—Integrated Biology at Agilent.
The integration of genomic, transcriptomic, proteomic and metabolomics is advancing rapidly, providing new insights into the study of biological response mechanisms. Recent published examples of pathway-driven multi-omics research show how these types of analyses can yield valuable information about drug responses, drug resistance, diagnostic markers, and fundamental disease/toxicity pathways.
The urgent need for a more mechanistic understanding of the ways in which chemicals modulate biological pathways is required in order to identify and better assess safety issues relating to a wide range of substances developed by the pharmaceutical, chemical, agricultural, biological and cosmetic industries. Omics technologies provide a valuable opportunity to refine existing methods and provide the basis for integrated testing strategies.
Integrated testing strategies include multi-omics data and modeling, using both in vivo and cell-based assays. These strategies are gaining traction as a viable approach in the development of a pathway-based mechanistic view of biochemically induced bioactivity.
Complete Omics Solution
Agilent’s pathway-based, multi-omics technologies work together to form a complete integrated biology platform. These technologies feature state-of-the-art instruments, reagents and software for genomics, proteomics, metabolomics, transcriptomics, and bioinformatics. For more information on Agilent’s Integrated Biology portfolio, please visit: Agilent Integrated Biology.
Company websiteAgilent Technologies